Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases

Bordigoni, Pierre; R, Turello; Clément, Laurence; Lascombes, P.; Leheup, B.; Ma, Genshan; Plenat, F

doi:10.1038/sj.bmt.1703424

Cited by 30 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Children receiving GH develop osteochondromas earlier and at a shorter time after transplantation than children not receiving GH. [45][46][47] These data suggest that in this population of children given TBI, use of GH may stimulate radiotherapy-disturbed epiphyses resulting in an increased incidence of osteochondromas. 45,47 GH recipients in the present study developed osteochondromas longer after transplantation but were younger at HCT than the non-GH-treated patients.…”

Section: Discussionmentioning

confidence: 92%

“…Radiation-induced osteochondromas occur at an incidence of 10% to 12% after radiotherapy and an incidence of 10% to 24% after TBI. [44][45][46][47] Younger children are at greatest risk because of their greater growth potential. Chemotherapy and radiotherapy can arrest growth and cause epiphyses to remain open longer than usual, permitting osteochondromas to develop.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Final adult height of patients who received hematopoietic cell transplantation in childhood

Sanders

Guthrie

Hoffmeister

et al. 2005

Blood

104

View full text Add to dashboard Cite

Growth impairment and growth hormone (GH) deficiency are complications after total body irradiation (TBI) and hematopoietic cell transplantation (HCT). To determine the impact of GH therapy on growth, the final heights of 90 GH-deficient children who underwent fractionated TBI and HCT for malignancy were evaluated. Changes in height standard deviation (SD) from the diagnosis of GH deficiency to the achievement of final height were compared among 42 who did and 48 who did not receive GH therapy. At HCT, GHtreated patients were younger (P ‫؍‬ .001), more likely to have undergone central nervous system irradiation (P ‫؍‬ .007), and shorter (P ‫؍‬ .005) than patients who did not receive GH therapy. After HCT, GH deficiency was diagnosed at 1.5 years (range, 0.8-9.5 years) for GH-treated and 1.2 years (range, 0.9-8.8 years) for nontreated patients. GH therapy was associated with significantly improved final height in children younger than 10 years at HCT (P ‫؍‬ .0001), but GH therapy did not impact the growth of older children.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Final adult height of patients who received hematopoietic cell transplantation in childhood

Sanders

Guthrie

Hoffmeister

et al. 2005

Blood

104

View full text Add to dashboard Cite

show abstract

“…34 Previously, we and others have reported osteochondromas arising in patients following ASCT for high-risk NB. 35,36 Since our previous report of five cases, 36 we have identified a further three cases. Other musculoskeletal complications including fractures and slipped capital femoral epiphyses were observed in six patients.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation

Trahair

Vowels

Johnston

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Yet spinal OCs are in fact rare, which has raised the possibility that vertebral bodies and pedicles may be inherently less predisposed to radiation-related or spontaneous OCs. 41,42 Spinal OCs were noted in two early reports on OCs and local RT, 9,10 but not in others, 6-8 and were not described in reports on toxicities of TBI 13,16,17,21-23 or in other reports with details on sites of OCs. 11,31,33 …”

Section: Discussionmentioning

confidence: 99%

Osteochondroma in long‐term survivors of high‐risk neuroblastoma

Kushner

Roberts

Friedman

et al. 2015

Cancer

View full text Add to dashboard Cite

Background Osteochondromas are benign bony protrusions that can be spontaneous or associated with radiation therapy (RT). Current treatment of high-risk neuroblastoma includes dose-intensive chemotherapy, local RT, anti-GD2 monoclonal antibody (MAb), and isotretinoin. Late effects are emerging. Methods We studied osteochondromas in 362 patients who were <10 years old when diagnosed with neuroblastoma; received MAb+isotretinoin since 2000; and survived ≥24 months from the first dose of MAb. The incidence rate of osteochondromas was determined using the competing risks approach where the primary event was osteochondroma calculated from the date of neuroblastoma diagnosis and the competing event was death without osteochondroma. Results Twenty-one osteochondromas were found in 14 patients who were 5.7-15.3 (median 10.4) years of age and 3.1-11.2 (median 8.2) years from neuroblastoma diagnosis. The cumulative incidence rate was 0.6% at five years and 4.9% at 10 years from neuroblastoma diagnosis. Nine osteochondromas were revealed incidentally during assessments of neuroblastoma disease status or bone age. Thirteen osteochondromas were outside RT portals and had characteristics of spontaneous forms. Complications were limited to pain necessitating resection in three patients, but follow-up is short at 0.3-7.7 (median 3.5) years. Conclusions Osteochondromas in long-term survivors of neuroblastoma should be expected because these benign growths can be RT-related and these patients undergo radiologic studies over years, are monitored for late toxicities through and beyond adolescence, and receive special attention (because of concern about relapse) if they develop a bony protuberance. A pathogenic role for chemotherapy, anti-GD2 MAb, or isotretinoin remains speculative.

show abstract

Osteochondroma after pediatric hematopoietic stem cell transplantation: report of eight cases

Cited by 30 publications

References 16 publications

Final adult height of patients who received hematopoietic cell transplantation in childhood

Final adult height of patients who received hematopoietic cell transplantation in childhood

Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation

Osteochondroma in long‐term survivors of high‐risk neuroblastoma

Contact Info

Product

Resources

About